HORMONE REPLACEMENT THERAPY MARKET ANALYSIS

Hormone Replacement Therapy Market Size and Trends

The global hormone replacement therapy market is estimated to be valued at USD 14.89 Bn in 2024 and is expected to reach USD 22.04 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.8% from 2024 to 2031.

To learn more about this report, request sample copy

The global hormone replacement therapy is expected to witness significant growth over the forecast period. Rising prevalence of hormonal deficiencies due to the increasing geriatric population is expected to drive the demand for hormone replacement therapy. Additionally, increasing consumer awareness about benefits of the treatment in managing menopausal symptoms is further expected to propel the market growth. However, risks and side effects associated with long-term use of hormone replacement therapy such as blood clots, heart attacks, and breast cancer could hamper the market growth.

Market Driver – Increasing Product Launches by Key Market Players

Market players are involved in launching new drugs and this is expected to drive growth of the global hormone replacement therapy market over the forecast period. For instance, in October 2021, Theramex, a pharmaceutical company, announced that it had launched Bijuva/Bijuve (estradiol and progesterone) across Europe and the U.K. Bijuva/Bijuve (estradiol and progesterone) is the first and only body-identical combined hormone therapy treatment for post-menopausal women.

Increasing prevalence of chronic conditions such as hypogonadism in adult men worldwide is expected to drive growth of the hormone replacement therapy market. For instance, in June 2021, according to the European Association of Urology, male hypogonadism is a disorder associated with decreased functional activity of the testes, with decreased production and/or action of androgens and/or impaired sperm production. This is caused by poor testicular function or as a result of inadequate stimulation of the testes by the hypothalamic-pituitary-gonadal (HPG) axis. Likewise, several congenital or acquired disorders causing impaired action of androgens have also been described. In men aged between 40 and 79 years old, the incidence of symptomatic hypogonadism varies between 2.1% and 5.7%. The incidence of hypogonadism has been reported to be 12.3 and 11.7 cases per 1,000 people per year in the U.S. Testosterone production declines as a function of age, and the prevalence of hypogonadism increases with aging.